1701434-52-7Relevant articles and documents
Efficient bluish green electroluminescence of iridium complexes with good electron mobility
Han, Hua-Bo,Wu, Zheng-Guang,Zheng, You-Xuan
, p. 13351 - 13357 (2018)
Two novel iridium(iii) complexes (Ir1 and Ir2), synthesized using 2′-(trifluoromethyl)-2,5′-bipyrimidine and 5-fluoro-2′-(trifluoromethyl)-2,5′-bipyrimidine as the main ligands, and tetraphenylimidodiphosphinate (tpip) as an ancillary ligand, were investigated. The introduction of a nitrogen heterocycle and CF3 substituent improves the electron mobility of the Ir(iii) complexes, which is beneficial for device performance. Both of the complexes emit bluish green photoluminescence with very high quantum efficiency yields (Ir1: λmax: 485/516 nm, ηPL: 89%; Ir2: λmax: 482/513 nm, ηPL: 95%) and good electron mobility. Organic light-emitting diodes (OLEDs) constructed with an ITO (indium tin oxide)/MoO3 (molybdenum oxide, 3 nm)/TAPC (di-[4-(N,N-ditolyl-amino)-phenyl]cyclohexane, 50 nm)/mCP (1,3-bis(9H-carbazol-9-yl)benzene, 5 nm)/Ir complex (6 wt%):PPO21 (3-(diphenylphosphoryl)-9-(4-(diphenyl-phosphoryl)phenyl)-9H-carbazole, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-phenyl)benzene, 50 nm)/LiF (1 nm)/Al (100 nm) structure showed good device performances. Device G1 based on Ir1 showed a ηc,max value of 62.99 cd A-1 with an EQEmax value of 23.5%. Owing to the slightly higher PL efficiency and lower LUMO levels of Ir2, which are beneficial for electron injection, the device based on Ir2 displayed a slightly better performance with a ηc,max value of 71.18 cd A-1 and an EQEmax value of 27.7%. Even at a practical brightness of 1000 cd m2, values of 57.39 cd A-1 and 22.3% could still be reached.
CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME
-
Paragraph 0131, (2018/06/15)
A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has superior TRPA1 antagonist activity, and the compound or a pharmaceutically acceptable salt thereof is useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO
-
Paragraph 772; 773, (2017/01/31)
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.
